Software company TrialAssure® announced today (April 7) that it is offering academic institutions free access to TrialAssure REGISTRY, a clinical trial disclosure reporting application. This offer is limited to the registry configurations for ClinicalTrials.gov, the U.S. Food and Drug Administration (FDA) clinical trial registry, and it includes one upgrade per year, keeping with technological advancements and any U.S. regulatory updates or changes to registry requirements.
Academic institutions can sign up for a TrialAssure subscription specific to this program—at no cost— allowing users free access for up to two years. TrialAssure, in providing access to the REGISTRY application, will ask participating academic institutions to make a commitment to transparency in research, including measured improvements to their registry compliance over a two-year period.
“We want to make sure that every clinical trial is reported in a timely manner, and our goal is to provide the tools to help where the need is most evident—in the academic setting,” says Mohamad Zahreddine, chief information officer for TrialAssure and a member of the Forbes Technology Council.
Government regulations in the U.S. and other global health authorities require the registration and subsequent posting of summary results for clinical trials. However, in review of compliance in the U.S., only 34% of clinical trials sponsored by academic institutions and similar groups are likely to be reported on time, according to AllTrials.
With this free, limited-time academic subscription program, institutions will have up to three professional and 20 reviewer level users within the TrialAssure REGISTRY application, will own and manage their data directly, and will have access to full training documentation.
“[We believe] that data transparency advances science and the development of new medicines,” says Kelly Vaillant, director of global transparency strategy and compliance with TrialAssure. “As an industry, we have a responsibility and obligation to make information about clinical trials available in a way that protects the patient’s privacy, but also allows for the benefits to science. If we can help organizations enhance transparency across their clinical research activities, which is needed, it’s a strong step in the right direction.”
Academic institutions have six months (until October 7, 2020) to express interest in this program. Those interested in gaining a free subscription can fill out this form: https://www.trialassure.com/contact-us/.
Edited by Gary Cramer
